Immunization Policy and Procedure Manual Update
This email is being sent to local health officers, Tribal health directors, VFC providers, VFA providers, and key DHS staff.
Updated COVID-19 Vaccine Sections
The Moderna, Novavax, and Pfizer COVID-19 vaccine (2023–2024 formula) sections have been updated to include the recommendation for persons aged 65 years and older to receive an additional dose of COVID-19 vaccine (2023–2024 formula) at least 4 months following their previous dose of (2023–2024 formula) COVID-19 vaccine.
Updated Td Vaccine Sections
The Td vaccine section has been updated to permit administration off-label among children aged <7 years for whom receipt of the pertussis component is contraindicated to complete the primary DTaP series. Appendix B (pediatric eligibility) has also been updated to reflect this change.
The Immunization Program policy and procedure manual may be accessed on SharePoint (PCA Portal). Once you are logged into SharePoint, navigate to the top ribbon, and select “Immunizations,” then look under “Immunization Documents,” and select the “Immunization Policy and Procedure Manual.”
Td Vaccine in Limited Supply
MassBiologics has discontinued production of their Td vaccine, TdVaxTM. Supply of TdVaxTM is anticipated to last through June. It is anticipated that the supply of Td vaccine in the US market will be constrained through 2024.
Sanofi, manufacturer of Tenivac®, is taking steps to augment their available supply of Td vaccine for the US and will be implementing ordering controls until the supply has increased.
As a result, CDC has put allocations into place for all three Td vaccine presentations. The Immunization Program will receive thresholds which will be less than our historical usage of Td vaccine. These thresholds will be refreshed monthly and are expected to remain level while ordering controls are in effect.
|
